

Healthy Ideas Healthy Returns

Programme

HIHR-13

Online Quickfire sessions, November 13 – 15, 2023

Live pitch event - Rotterdam Science Tower, November 22, 2023

Supported by



Rotterdam Square
Where tech meets healthcare

Empowered by



Health~Holland
SHARED CHALLENGES. SMART SOLUTIONS



Participating Public Research Organisations (PROs)

Supporting PROs



Regular PROs



Preferred partner



Golden partner



Silver partners



HIHR supporters

V-Bio Ventures | NLC Health | Thuja | General Inception | imec.istart.nl

Content

Content	3
<i>HIHR pitch programme – November 22, 2023</i>	4
<i>HIHR pitch & Q&A sessions – Start up pitches</i>	5
<i>Schedule HIHR online Quickfire sessions, November 13 - 15, 2023</i>	6
Sponsors and supporters	7
Preferred partner	7
Golden Partner	8
Silver Partner	8
Supporters of HIHR.....	9
Event sponsors	10
Insight- and Panel Sessions	11
<i>All the sweat you cannot see</i>	11
Panel discussion <i>How to mate technology with money</i>	11
Registration	12
Venue	12
Contact	13

HIHR pitch programme – November 22, 2023

HIHR
Healthy Ideas
Healthy Returns

Programme

- 11.45 Registration desk open – **11th floor**
- 12.00 *Welcome Lunch* – **11th floor**
- 13.00 **Healthy Ideas, Healthy Returns** 13th edition – **9th floor**
- Opening* by the moderator - **Jeff Skinner**, Teaching Fellow, London Business School
- Welcome* – **Claar-els van Delft**, General Manager HIHR
- Short Intro EIT Health* - **Bart Haex**, Director of Business Development & External Relations at EIT Health BeNe
- J&J Innovation recap* – **Tessy Korthout**, R&D Innovation scout - The Janssen Pharmaceutical Companies of Johnson & Johnson
- HIHR Pitch & Q&A session I (projects listed at page 5)
- All the sweat you cannot see* - Insight session
With **Maxime Nachit** (HepaVue DX) and **Carla van Heck** (HIHR)
- 14.45 *Coffee break* – **11th floor**
- 15.15 HIHR Pitch & Q&A session II (projects listed at page 5) – **9th floor**
- 16.30 *How to mate technology with money* - Panel discussion
With **Ivan Burkov** (INKEF Capital) and **Duko Drijfhout** (Erasmus MC)
- Closure*
- 17.00 *Networking drinks & bites* – **11th floor**

HIHR pitch & Q&A sessions – Start up pitches

Summaries of the Spin off projects will be sent upon registration.

HIHR Pitch & Q&A session I

Spatium Medical BV - *Bringing smart insufflation to the world of laparoscopy*
Willem Mees van der Bijl, CEO - Erasmus MC, MedTech & Diagnostics

HepaVue Dx - *A first-in-class tool to replace biopsy in liver diseases*
Maxime Nachit, CEO – UCLouvain, Therapeutics & Biotech, MedTech & Diagnostics

IProtics - *Superior small molecules for the treatment of haematological cancers*
Patrick Dekker, Co-founder - Leiden University, Therapeutics & Biotech

SimpleFluidics - *One finger-press away from decentralized health car*
Dries Vloemans, Leading role in technology and business development - KU Leuven R&D, MedTech & Diagnostics

4Tissue* - *We develop a bioresorbable injectable for Breast Tissue Replacements*
An van den Bulcke, COO – uGhent, Therapeutics & Biotech, MedTech & Diagnostics

HIHR Pitch & Q&A session II

Madglove Amsterdam B.V. - *Helping people get a grasp on hand spasticity*
Madaline Riurean, CEO - Vrije Universiteit Amsterdam, MedTech & Diagnostics

AptaQuest - *Providing the ultimate resolution for proteomics*
Carlos De Lannoy, Co-founder - TU Delft / Delft Enterprises, MedTech & Diagnostics

ALPS - *Automating Library Prep for Sequencing*
Ying Ting Set, Co-founder – imec, Therapeutics & Biotech, MedTech & Diagnostics, eHealth & Datascience

Avalanche Medical BV - *Making surgical treatment of cartilage defects sustainable with a biomimetic and joint-preserving knee resurfacing implant.*
Alex Roth, CSO and Co-Founder – TU Eindhoven & U Maastricht, MedTech & Diagnostics

Trince* - *We develop an innovative, gentle new high throughput transfection technology*
Philip Mathuis, CEO & Co-founder – UGhent, Therapeutics & Biotech

HIHR Pitches will last for a maximum of 7 min presentation, followed by 4 min Q&A (+1 min change).

Due to the density of the programme we must strictly adhere to the schedule. We will close the doors as to not disturb the pitch presentations.

* *Alumni pitch*; 5 min extra to present the journey from their first HIHR-pitch till now

Schedule HIHR online Quickfire sessions, November 13 - 15, 2023

HIHR offers new entrepreneurial teams/KTOs venture ideas, not pitch ready yet, the opportunity to test their idea / concept with investors, entrepreneurs and corporates in a 45 minute online session. We highly appreciate your feedback and encourage all investors to participate in these informal sessions to help young entrepreneurial teams with feedback. These sessions for pre-mature projects will take place *online* via MS Teams, according to the following schedule:

Quick fire sessions		
Monday November 13	09.00 – 09.45	Flexsupp - <i>The Solution For All Women With Pelvic Organ Prolapse</i> MedTech & Diagnostics – Radboud UMC
	12.00 – 12.45	Pulso - <i>Accelerate innovation in vascular devices</i> MedTech & Diagnostics - University of Mons
	17.00 – 17.45	DOPLr - <i>The all-in-one data platform for Medical Researchers</i> MedTech & Diagnostics, eHealth & Datascience – KU Leuven
Tuesday November 14	09.00 – 09.45	SCREEN4PN - <i>Screening platform for therapies for peripheral neuropathies (SCREEN4PN) in induced pluripotent stem cell derived 2D and 3D models</i> Therapeutics & Biotech – U Antwerp
	12.00 – 12.45	ReWrite - <i>stem cell generation and genome editing services</i> Therapeutics & Biotech - stem cell institute Leuven
	17.00 – 17.45	Modular Therapeutic - <i>Modular therapeutic target identification for drug repurposing</i> Therapeutics & Biotech - Netherlands Cancer Institute/ Antoni van Leeuwenhoek
Wednesday November 15	09.00 – 09.45	OPE group - <i>Thonis – Nature automated drug discovery</i> Therapeutics & Biotech - U Leiden
	12.00 – 12.45	Unlocking the Power of Yeast Microfactories - <i>Revolutionizing Strain Engineering with CRISPR-Powered innovation</i> Therapeutics & Biotech, MedTech & Diagnostics – Wageningen U&R

You can mark your interest on the online registration form. Calendar invitations will be sent with the online MS Teams link, to indications 'Highly interested'. Indications 'willing to help' receive an *optional* calendar invite.

Summaries of the Quickfire projects will be sent to you upon registration.

Sponsors and supporters

Preferred partner



JNJ Innovation

[Johnson & Johnson Innovation](#) seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve people's lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.

Our mission is to unlock the potential of life science innovation no matter where it originates. We aim to solve the world's toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere.

We are comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration:

- Our [Innovation Centers](#) are regional hubs to access the best science and technology in the region. [Make the connection](#) if you are an entrepreneur or an early-stage consumer or medical device company, or a biopharmaceutical company seeking a collaboration to advance a program which is pre-proof of concept in humans.
- Our [JLABS network](#) of incubators support entrepreneurs launching consumer, medical device, or biopharmaceutical companies. [Make the connection](#) if you are seeking incubation space for your early-stage company, or seeking to expand your start-up through an exchange of ideas and collaboration.
- Our [JJDC, Inc.](#) strategic venture arm invests across all sectors and at all stages, from seed-level start-ups to Series B and beyond. [Make the connection](#) if you are seeking a strategic venture partner.
- Our [Janssen Business Development](#) team seeks to identify collaborative opportunities that will create transformative value for our partners and the world. [Make the connection](#) if you are an established pharmaceutical company, or mid-sized to large biotechnology company, and seek a collaboration or merger & acquisition discussion.

Feel free to contact our Benelux External Innovation Partnering leads [Tessy Korthout](#), [Viggo van Tendeloo](#) or [Peter Roevens](#).

Golden Partner



EIT Health

EIT Health is a community of world-leading health innovators facing Europe's biggest health challenges, by overcoming barriers, challenging convention, and delivering innovative products and services to those in need. Approximately 150 world-class partner organisations collaborate cross-border to implement the 'Knowledge triangle' principle of business, innovation, and education.

Our pan-EU representation via eight Regional Innovation Hubs (RIHs) build strong ecosystem innovation clusters, including Austria, BeNeLux, France, Germany, Scandinavia, Spain, Ireland-UK and 'Innostars', which represents RIHs with moderate innovation pace, such as Hungary, Italy, Poland, and Portugal, as well as 13 further regions across Central, Eastern and Southern Europe from the EIT Regional Innovation Scheme.

Our Business Creation programmes supported more than 1,200 start-ups by 2023, acting as catalyst for new business growth, shortening time-to-market for life-changing products and services, while creating new jobs and fostering a thriving European health economy. EIT Health's Business Creation pillar was awarded in the "Most Promising – Young Programme" category of UBI Global's prestigious ranking of incubators and accelerators worldwide. <https://eithealth.eu>
For inquiries or follow up talks please contact nicolas.vandekerhof@eithealth.eu

Silver Partner

INKEF

INKEF Capital is a leading venture capital firm based in Amsterdam with a proven history in backing promising early stage companies in Europe. INKEF takes pride in being a patient, long-term investor with the ability to support companies through several funding rounds all the way up to IPO. From the early stages of being a technology or life science venture, INKEF supports entrepreneurs building their ideas into successful international businesses. Inkef's investments include Onward Medical, Castor, iOnctura, Cardior and GitLab, Remote among others. For more information please visit: www.inkef.com

Bioqube Ventures

Bioqube Ventures a specialist life sciences investment firm founded in 2016. The team consist out of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth paths. With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe. www.bioqubeventures.com



Supporters of HIHR

NLC Health

Pain monitoring systems, ultrasound cancer detection, light therapy for newborns- these are just some of the life-changing technologies that NLC has brought to those in need- that would have otherwise been abandoned. Join us in nurturing healthtech ventures to advance health. www.nlc.health

V-Bio

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world's premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors www.v-bio.ventures.

Thuja

Thuja Capital Management (Thuja) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. In addition to generating a financial return for its investors, Thuja's investments positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital to daring entrepreneurs with ground-breaking product concepts locally. For more information visit www.thujacapital.com.

General Inception

General Inception partners with scientific founders - often first time founders - to ignite their innovation and create transformational companies. We are co-founders bringing together domain expertise, seasoned executive talent, infrastructure resources, and capital to nurture company growth from inception. We started our journey in Palo Alto, California and are now expanding in the Benelux and rest of Europe. www.generalinception.com

Imec.istart.nl

imec.istart.nl, powered by imec and Novel-T, offers tech startups pre-seed funding (between 100.000 and up to 250.000 euro) and tailored support to succeed and grow globally. We have the ambition to support at least 15 high-potential start-ups per year in the Netherlands – often as their first investor. As an investor, we're in it for the long run. www.imecistart.novelt.com

Event sponsors

Top Sector Life Science & Health

Top Sector Life Sciences & Health (Health~Holland) works together with public and private parties to promote the economic opportunities of the societal theme Health & Care of the Dutch cabinet's Mission-driven Top Sectors and Innovation Policy. The coalition does this on the basis of the five Health & Care missions, formulated by the Ministry of Health, Welfare and Sport. The central mission is as follows: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%. There are four underlying missions that contribute to this central mission through changes to lifestyle and living environment, offering more care in the right place and better perspectives for people with chronic diseases, lifelong disabilities and dementia. With this approach, the Netherlands seeks to effectively tackle major societal challenges. Industry can optimally respond to the economic opportunities that these challenges bring.



Rotterdam Square

Rotterdam Square is the organization that connects the Life Sciences & Health ecosystem in the Rotterdam region. Located in the vibrant heart of Rotterdam, and as campus organization of the new Erasmus MC Campus, Rotterdam Square creates partnerships and collaborations between experts in healthcare, science and technology, from academia and industry, to accelerate Health&Tech innovations and create healthcare solutions for the future.



Rotterdam Square connects researchers and companies on a regional, national and international level, organizes networking events and supports companies in creating promising partnerships, drawing upon our extensive knowledge of the Life Sciences & Health sector and working closely together with the Municipality of Rotterdam and Erasmus MC. We help companies to successfully integrate in the Rotterdam ecosystem and be part of the Dutch connected Life Sciences & Health metropolis, to establish new healthcare innovations that benefit our patients.

For more information, please visit our website www.rotterdamsquare.nl or contact Sharon Mullen, Senior Account Manager at Rotterdam Square - sharon.mullen@rotterdamsquare.nl - or Carola Immerzeel-Goosens from the Erasmus MC Technology Transfer Office and Incubator, and Project Manager at Rotterdam Square - c.goosens@erasmusmc.nl.

Come join us at our stand November 22, we're excited to meet you there!

Interested in becoming a sponsor or supporter as well? Just send an email to carla@hihr.eu to check out the options.

Insight- and Panel Sessions

All the sweat you cannot see

HIHR brings early scientific ventures and VC's together to bridge the gap when spinning off. In the preparations and during the event we do our best to facilitate this and give all sides the best shot at a good introduction. We notice that not always our stakeholders understand what we are doing in the preparations and what our added value is. During this 15 minutes session, we will give you a brief insight in this process with the help of where we discuss this more in depth.

With **Maxime Nachit**, HepaVue DX and **Carla van Heck**, HIHR.

Panel discussion How to mate technology with money

There is a chronic failure in the market for investment in early-stage technologies. Although there are enough investors hunting for deals and many entrepreneurial researchers trying to get their attention, these two vital resources - money and technology - usually don't mate.

Why is this and what can be done?

Well, many of the usual sources of market failure – search costs, externalities, insufficient of buyers and sellers, information asymmetry and transaction costs - apply to the market for very early-stage technologies. In fact they apply more to early stage technologies than their later stage cousins:

- Short of 'walking the corridors', where do you (investors) find promising technologies (and aspiring founders) amongst the thousands of researchers in universities & PROs?
- If you do find and spend time advising a good opportunity - how can you be sure that they'll end up coming to you – if you do invest then how do you secure your position for future rounds if the technology blossoms (maybe you just wait for others to invest and then swoop in at a later round).
- There are plenty of researchers who want your cash, but how many are there who deserve it – and are there sufficient numbers to make early-stage investing a worthwhile business?
- There are few solid results at an early stage. The only way of minimising risk is to carry out extensive due diligence on technology and team. This is expensive, even more so than at a later stage, especially as a proportion of the smaller sums invested per project.
- Transaction costs (legal and portfolio management) are at best independent of deal size and thus can become disproportionate.

These are gloomy observations – and go a long way to explain why so few investors dabble at the very early stage, preferring to wait for later rounds (though of course if everyone waits then there are no later rounds!) It is this conclusion (the so-called, 'valley of death'), that has compelled governments to create 'proof of concept' funds with varying degrees of success.

Another is the creation of networks and forums – like HIHR – that concentrate investors and entrepreneurs in one place at one time (everyone, everything, all at once) – someone still needs to pay but there are huge economies of scale so it should be worth everyone chipping in.

In this session we'd like to stimulate a discussion that starts with the reality of this stultifying market failure and then figure out what – if anything – can be done to defeat it.

With **Ivan Burkov**, INKEF Capital and **Duko Drijfhout**, Erasmus MC

Registration

To secure the direct connection and intimate atmosphere, HIHR-events are 'invitation-only'. If you would like to join us and are *not* on our investor/corporate mailing-list yet, you're very welcome to send an email to clear-els@hihr.eu.

Investors/corporates will receive the link to the investor-registration form by email.

KTO/Spin off team-members that would like to join our event in Rotterdam need to register individually via this [KTO/Spin off event registration form](#).

On line event-registration is a **pre-requisite** to participate in Rotterdam. Registration closes November 15.

Please contact clear-els@hihr.eu for any inquiries.

A syllabus with summaries of all selected projects will be sent upon registration.

Venue

The event will take place in the [Rotterdam Science Tower](#), Marconistreet 16, 3029 AK Rotterdam, the Netherlands.

→ Please note that:

- Registration, wardrobe, lunch, breaks and drinks will be served on the [11th floor](#).
- The pitch presentations will be given on the [9th floor](#).

Please pick up your badges at the 11th floor first.

PARKING

Take the first garage entrance marked "**P Rotterdam Science Tower**". Then walk via the side of the parking garage to the entrance on the western side of Rotterdam Science Tower. Exiting the parking garage is possible without an exit ticket.

PUBLIC TRANSPORT

Take metro, tram or bus to **Marconiplein** station. The Rotterdam Science Tower is a 3-minute walk away.

Contact

For additional information and inquiries please contact:

Healthy Ideas ^{HIHR}
Healthy Returns

Claar-els van Delft
Mob +31 6 2848 0549
Claar-els@hihr.eu
www.hihr.eu